ZS Pharma, Inc. Research and Development Expense
ZS Pharma, Inc. reported Research and Development Expense of $18.40 million for the 3-month period ending 2015-09-30, per its 10-Q filed 2015-11-09.
Discontinued › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2015-11-09
- ZS Pharma, Inc. research and development expense for the quarter ending 2015-09-30 was $18.40M, a 46.74% increase year-over-year.
- ZS Pharma, Inc. research and development expense for the quarter ending 2015-06-30 was $17.29M, a 48.43% increase year-over-year.
- ZS Pharma, Inc. research and development expense for the quarter ending 2015-03-31 was $15.32M, a 123.48% increase year-over-year.
- ZS Pharma, Inc. research and development expense for the quarter ending 2014-12-31 was $14.57M, a 111.83% increase year-over-year.
- ZS Pharma, Inc. research and development expense for fiscal 2014 was $45.62M, a 84.23% increase from fiscal 2013.
- ZS Pharma, Inc. research and development expense for fiscal 2013 was $24.76M, a 254.30% increase from fiscal 2012.
- ZS Pharma, Inc. research and development expense for fiscal 2012 was $6.99M.
| Period end | Research and Development Expense 3 month | Research and Development Expense 3 month as first filed | Research and Development Expense 6 month | Research and Development Expense 6 month as first filed | Research and Development Expense 9 month | Research and Development Expense 9 month as first filed | Research and Development Expense 12 month |
|---|---|---|---|---|---|---|---|
| 2015-09-30 | $18.40M 10-Q · filed 2015-11-09 | $35.69M derived: sum of 2 quarters · filed 2015-11-09 | $51.01M 10-Q · filed 2015-11-09 | $65.58M derived: sum of 4 quarters · filed 2015-11-09 | |||
| 2015-06-30 | $17.29M 10-Q · filed 2015-08-06 | $32.61M 10-Q · filed 2015-08-06 | $47.18M derived: sum of 3 quarters · filed 2015-08-06 | $59.72M derived: sum of 4 quarters · filed 2015-11-09 | |||
| 2015-03-31 | $15.32M 10-Q · filed 2015-05-11 | $29.89M derived: sum of 2 quarters · filed 2015-05-11 | $42.43M derived: sum of 3 quarters · filed 2015-11-09 | $54.08M derived: sum of 4 quarters · filed 2015-11-09 | |||
| 2014-12-31 | $14.57M 10-K · filed 2015-03-13 | $27.11M derived: sum of 2 quarters · filed 2015-11-09 | $38.76M derived: sum of 3 quarters · filed 2015-11-09 | $45.62M 10-K · filed 2015-03-13 | |||
| 2014-09-30 | $12.54M 10-Q · filed 2015-11-09 | $10.92M 10-Q · filed 2014-11-10 | $24.19M derived: sum of 2 quarters · filed 2015-11-09 | $31.04M 10-Q · filed 2015-11-09 | $26.16M 10-Q · filed 2014-11-10 | $37.92M derived: sum of 4 quarters · filed 2015-11-09 | |
| 2014-06-30 | $11.65M 10-Q · filed 2015-08-06 | $9.98M 10-Q · filed 2014-08-14 | $18.50M 10-Q · filed 2015-08-06 | $15.23M 10-Q · filed 2014-08-14 | $25.38M derived: sum of 3 quarters · filed 2015-08-06 | $32.52M derived: sum of 4 quarters · filed 2015-08-06 | |
| 2014-03-31 | $6.85M 10-Q · filed 2015-05-11 | $13.73M derived: sum of 2 quarters · filed 2015-05-11 | $20.87M derived: sum of 3 quarters · filed 2015-05-11 | $27.21M derived: sum of 4 quarters · filed 2015-05-11 | |||
| 2013-12-31 | $6.88M 10-K · filed 2015-03-13 | $14.02M derived: sum of 2 quarters · filed 2015-03-13 | $20.35M derived: sum of 3 quarters · filed 2015-03-13 | $24.76M 10-K · filed 2015-03-13 | |||
| 2013-09-30 | $7.14M 10-K · filed 2015-03-13 | $13.47M derived: sum of 2 quarters · filed 2015-03-13 | $17.88M 10-Q · filed 2014-11-10 | ||||
| 2013-06-30 | $6.33M 10-K · filed 2015-03-13 | $10.74M 10-Q · filed 2014-08-14 | |||||
| 2013-03-31 | $4.41M 10-K · filed 2015-03-13 | ||||||
| 2012-12-31 | $6.99M 10-K · filed 2015-03-13 |